文献速递白血病造血干细胞移植与细胞治疗

B细胞急性淋巴细胞白血病CD19靶向治疗后CD19阴性复发的临床意义

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.
PubMed 文献 · Am J Hematol · 2026-07-23

该回顾性研究分析65例接受CD19靶向治疗后出现CD19阴性复发的成人ALL患者,中位EFS为3.1个月,中位OS为9.9个月。接受≥2种CD19靶向治疗与更差的EFS和OS相关。首次挽救治疗的完全缓解率为47.5%,CD19复发后任意时间完全缓解率为72.1%。

要点

  • CD19阴性复发后中位EFS仅3.1个月,中位OS为9.9个月,预后差。
  • 接受≥2种CD19靶向治疗是EFS和OS的不良预后因素。
  • 部分患者可再次表达CD19,且再接受CD19靶向治疗均有效。

核心结论

  • CD19靶向治疗后CD19阴性复发的成人ALL患者结局差且治疗选择有限。
  • 因缺乏CD19阳性复发对照队列,CD19阴性的独立预后影响无法确定。

研究设计与样本

  • 回顾性分析65例接受CD19靶向治疗后出现CD19阴性复发的成人ALL患者。

主要发现

  • TP53突变和BCR::ABL1-like ALL各占27.7%(n=18)。
  • 46例(70.8%)接受过1种CD19靶向治疗,19例(29.2%)接受过≥2种。
  • 60例(92.3%)接受过贝林妥欧单抗,23例(35.4%)接受过CAR T细胞治疗。
  • 中位EFS为3.1个月(95% CI,2.5-4.5),中位OS为9.9个月(95% CI,6.8-24.7)。
  • 多因素分析中,接受≥2种CD19靶向治疗与更差EFS相关(HR 2.17,95% CI,1.10-4.29;p=0.03)和更差OS相关(HR 3.05,95% CI,1.40-6.62;p=0.005)。

关键数值与推荐

  • 首次挽救治疗后完全缓解率为47.5%,CD19复发后任意时间完全缓解率为72.1%。
  • 从最近一次CD19靶向治疗开始至CD19阴性复发的中位时间为155天(范围,13-1946)。
  • 整个队列中位随访时间为32.7个月(IQR,15.1-90.3)。

临床怎么用

  • CD19阴性复发后应积极考虑挽救治疗,但需认识其预后差。
  • 既往接受多种CD19靶向治疗的患者预后更差,需谨慎评估治疗策略。
  • 可评估CD19再表达,部分患者仍可能从再次CD19靶向治疗中获益。

局限性

  • 缺乏CD19阳性复发对照队列,无法确定CD19阴性的独立预后影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed therapy remains the mainstay treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). However, treatment patterns and outcomes following CD19-negative (CD19-) relapse remain poorly defined. We retrospectively analyzed 65 adult patients with ALL who developed CD19-relapse after CD19-directed therapy. TP53 mutations and BCR::ABL1-like ALL were each identified in 27.7% (n = 18) of patients. Forty-six patients (70.8%) received one CD19-targeted therapy, whereas 19 patients (29.2%) received ≥ 2 prior to CD19-relapse. Overall, 60 patients (92.3%) received blinatumomab, and 23 (35.4%) received CAR T-cell therapy. The median time from the initiation of the most recent CD19-targeted therapy to CD19-relapse was 155 days (range, 13-1946). The median follow-up of the entire cohort was 32.7 months (IQR, 15.1-90.3). The median event-free and overall survival (EFS and OS) was 3.1 months (95% CI, 2.5-4.5) and 9.9 months (95% CI, 6.8-24.7), respectively. In multivariate analysis, receipt of ≥ 2 CD19-directed therapies was associated with both inferior EFS and OS, HR 2.17 (95% CI, 1.10-4.29; p = 0.03) and HR 3.05 (95% CI, 1.40-6.62; p = 0.005). The complete remission rate following first salvage therapy was 47.5% and 72.1% any time following CD19-relapse. Sixteen (34.8%) of 46 patients evaluated had subsequent CD19 re-expression, 5 of whom subsequently received CD19-directed therapy, and all 5 patients responded. Patients with ALL who develop CD19-relapse after CD19-directed therapy have poor outcomes and limited therapeutic options. However, since this study lacked a comparator cohort of patients with CD19-positive relapse, the independent prognostic impact of CD19 negativity could not be determined.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Othman T, Agrawal V, Song JY, et al. Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia. Am J Hematol. 2026. PMID: 42493343. doi:10.1002/ajh.70450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。